Insilico Medicine and Menarini Group’s Stemline Therapeutics Announce Second Exclusive Licensing Agreement for AI-Discovered Oncology Drug Candidate

Second Collaboration:
Insilico Medicine and Menarini Group's Stemline Therapeutics have entered into a second exclusive licensing agreement for an AI-discovered oncology drug candidate, following their successful 2024 partnership for MEN2312, a KAT6 inhibitor14.

Deal Terms:
The agreement includes a $20 million upfront payment to Insilico, with potential total payments exceeding $550 million, alongside tiered royalties14.

Drug Candidate:
The new preclinical asset, identified through Insilico’s generative AI platform, demonstrates broad anti-tumor activity across multiple solid tumor types14.

Previous Success:
MEN2312, the first licensed drug candidate, has quickly advanced into Phase 1 trials for metastatic ER+/HER2- breast cancer, showing promise in blocking estrogen receptor activity at the transcription level12.

Partnership:
The collaboration highlights the efficiency and strategic commitment of Menarini Stemline in rapidly delivering novel therapeutic solutions to cancer patients14.

AI-Driven Innovation:
Insilico Medicine's use of generative AI in drug discovery underscores its leadership in the field and its potential to address high unmet needs in oncology14.

Sources:

1. https://www.biopharmatrend.com/post/1103-insilico-medicine-licenses-second-ai-generated-cancer-drug-candidate-in-a-550m-deal/

2. https://www.menarini.com/en-us/news/news-detail/menarini-group-and-insilico-medicine-enter-global-exclusive-license-agreement-for-novel-kat6-inhibitor-for-potential-breast-cancer-treatment-and-other-oncology-indications

4. https://www.prnewswire.com/news-releases/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology-302347884.html